Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Class E basic helix-loop-helix protein 40 (BHLHE40, also known as DEC1, SHARP2, STRA13, and other aliases) is a transcription factor belonging to the basic helix-loop-helix (bHLH) family, characterized by a bHLH DNA-binding domain and an orange domain[1][4][5]. BHLHE40 regulates transcription by binding to E-box (CACGTG) sequences and acts primarily as a repressor of clock genes and clock-controlled genes, serving a central role in circadian rhythm regulation and functioning in a distinct autoregulatory feedback loop[3]. It is expressed in various tissues and regulates multiple biological processes, including cell differentiation, cell cycle progression, apoptosis, immune activation/modulation, adipogenesis, skeletal muscle regeneration, and neurogenesis[1][5][6]. BHLHE40 function is context-dependent; it may promote or suppress tumorigenesis in different cancer types, often responding to hypoxia and interacting with key cellular pathways, including PI3K/Akt/mTOR and STAT1 signaling[1][2]. Relevant in both diabetes and cancer, it is also induced by TGF-β and hypoxia signaling. The gene is located on chromosome 3p26.1 and can form homo- or heterodimers, especially with BHLHE41. BHLHE40's expression level and activity are biomarkers for cancer progression and grade, but the highly context-specific nature of its actions in disease means its targeting presents therapeutic challenges due to its dual tumor suppressor/promoter roles[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Class E basic helix-loop-helix protein 40 (BHLHE40).